Table 2.
Numbers, mortality rates, absolute rate differences, and adjusted hazard ratios of postfracture mortality for different prefracture bisphosphonate use
| No. of deaths | No. of individuals | Days of follow-upa, median (IQR) | MR/100 PY (95% CI) | RD/100 PY (95% CI) | HRb (95% CI) | |
|---|---|---|---|---|---|---|
| Overall | ||||||
| Continued use | 84 | 251 | 597 (270.5 to 927.5) | 19.7 (15.5-23.9) | 0 | 1 |
| Discontinued for 1 y | 29 | 50 | 533 (240.5 to 1049.25) | 26.1 (16.6 to 35.6) | 6.41 (−3.99 to 16.82) | 0.66 (0.35 to 1.27) |
| Discontinued for 2 y | 26 | 64 | 317.5 (128 to 951.25) | 36.7 (22.6 to 50.8) | 16.98 (2.25 to 31.70) | 1.13 (0.63 to 2.03) |
| Alendronate | ||||||
| Continued use | 53 | 146 | 614.5 (267.5 to 973.25) | 20.9 (15.2 to 26.5) | 0 | 1 |
| Discontinued for 1 y | 13 | 32 | 692.5 (384 to 1075.5) | 19.4 (8.9 to 30.0) | −1.43 (−13.39 to 10.52) | 0.59 (0.29 to 1.18) |
| Discontinued for 2 y | 15 | 34 | 526.5 (194 to 978.75) | 29.3 (14.5 to 44.1) | 8.43 (−7.41 to 24.28) | 1.05 (0.57 to 1.93) |
| Risedronate | ||||||
| Continued use | 31 | 105 | 573 (275 to 898) | 18.1 (11.7 to 24.4) | 0 | 1 |
| Discontinued for 1 y | 16 | 18 | 362.5 (172.5 to 861.5) | 36.4 (18.6 to 54.2) | 18.31 (−0.61 to 37.22) | 2.37 (1.24 to 4.53) |
| Discontinued for 2 y | 11 | 30 | 172.5 (116.5 to 717) | 56.1 (22.9 to 89.2) | 38.02 (4.28 to 71.77) | 3.08 (1.48 to 6.41) |
Abbreviations: HR, hazard ratio; IQR, interquartile range; IR, incidence rate; MR, mortality rate; PY, person-year; RD, rate difference.
a Days of follow-up are the number of days from admission to date of death or end of study, whichever occurred earlier.
b Adjusted for year of fracture, sex, age, hospital frailty risk score, type and region of residence, type of oral bisphosphonates, and interaction term between different bisphosphonate use trajectories and type of oral bisphosphonates.